Maturation of spiking activity in trout retinal ganglion cells coincides with upregulation of Kv3.1- and BK-related potassium channels.
Developmental changes in membrane excitability and the potassium channel profile were monitored in acutely isolated trout retinal ganglion cells by patch-clamp recording in combination with single-cell RT-PCR. During embryonic development in the egg, a sustained above-threshold stimulation of ganglion cells elicited in most cases only a single spike response. After hatching, the proportion of multiply spiking cells increased strongly and the ability of spike frequency coding was acquired. This was accompanied by the occurrence of a highly tetraethylammonium (TEA)- and quinine-sensitive delayed rectifier current, which gradually masked a rapidly inactivating A-type potassium current that was predominant at earlier stages. Pharmacology of the delayed rectifier current closely matched those of recombinant Traw1, a Kv3.1-related potassium channel in trout. The appearance of this current correlated closely with initial expression of Traw1 and Traw2 channel transcripts, as revealed by multiplex single-cell RT-PCR, whereas mRNA, encoding Shaker-related channel genes in trout (termed Tsha1-Tsha4), were already detectable at early embryonic stages. Iberiotoxin-sensitive, calcium-activated potassium currents (BK) were extremely low before hatching, but increased significantly thereafter. These developmental changes in potassium channel expression occurred after the arrival of retinal fibers in the optic tectum and the initiation of synapse formation in the visual center. It is suggested that early expressed Shaker-related potassium channels could act to influence neuronal differentiation, whereas proper neuronal signaling requires expression of Kv3.1- and BK-related potassium channels.
Henne
Jutta
J
Department of Neurobiology, University of Osnabrück, Osnabrück, Germany.
Jeserich
Gunnar
G
D000375:Aging / Q000502:physiology; D018712:Analgesics, Non-Narcotic / Q000494:pharmacology; D000818:Animals; D016587:Antimutagenic Agents / Q000494:pharmacology; D015152:Blotting, Northern; D003035:Cobalt / Q000494:pharmacology; D004307:Dose-Response Relationship, Radiation; D004531:Eggs; D004546:Elapid Venoms / Q000494:pharmacology; D004558:Electric Stimulation; D018507:Gene Expression Regulation, Developmental; D066298:In Vitro Techniques; D007814:Larva / Q000166:cytology / Q000254:growth & development / Q000502:physiology; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000502:physiology*; D009479:Neuropeptides / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D017686:Oncorhynchus mykiss; D018408:Patch-Clamp Techniques / Q000379:methods; D010455:Peptides / Q000494:pharmacology; D026902:Potassium Channel Blockers / Q000494:pharmacology; D015221:Potassium Channels / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D024681:Potassium Channels, Calcium-Activated / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D024642:Potassium Channels, Voltage-Gated; D011803:Quinine / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D012160:Retina / Q000166:cytology* / Q000502:physiology; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D051670:Shaw Potassium Channels; D019789:Tetraethylammonium / Q000494:pharmacology
D018712:Analgesics, Non-Narcotic; D016587:Antimutagenic Agents; D004546:Elapid Venoms; D009479:Neuropeptides; D010455:Peptides; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D024681:Potassium Channels, Calcium-Activated; D024642:Potassium Channels, Voltage-Gated; D012333:RNA, Messenger; D051670:Shaw Potassium Channels; D003035:Cobalt; D019789:Tetraethylammonium; C020273:dendrotoxin; C064719:iberiotoxin; D011803:Quinine; C018021:cobaltous chloride